Anti-CXCR4/CD184 Antibody (Ulocuplumab)
Catalog No.
F1107
Anti-CXCR4/CD184 Antibody (Ulocuplumab)
Featured Products
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocplumab induces apoptosis in cancer cells and can inhibit CXCL12-mediated migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation. Ulocplumab shows anti-tumor activity in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and multiple myeloma transplant models.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
150 kDa
Dry ice
1375830-34-4
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
MDX-1338, BMS-936564, F7
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P61073
Human
Unconjugated
Monoclonal
Protein A
IgG4
ELISA, FACS, Kinetics, Functional assay, Animal Model
Human CXCR4 / CD184 Romas cells were stained with Anti-CXCR4/CD184 Antibody (Ulocuplumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS
CXCR4 / CD184
Please avoid freeze-thaw cycles.